seco-duba

Seco-DUBA is an anticancer DNA alkylating agent and prodrug of DUBA, which can be used as a cytotoxic antibody-drug conjugate (ADC). It has an IC50 of 18 nM against KB and 430 pM against SK-OV-3, and can be converted into DUBA with higher stability and activity in vivo.

Seco-DUBA hydrochloride, a toxin used in the antibody-drug conjugate (ADC) SYD985.

Vc-seco-DUBA (Duocarmazine) is a linker-payload conjugate designed for the synthesis of Antibody-Drug Conjugates (ADCs). It consists of the potent DNA alkylating payload DUBA (a duocarmycin analog) connected via the Vc-seco linker. This conjugate is engineered to enable the targeted delivery of highly cytotoxic DNA-alkylating agents specifically to tumor cells through antibody guidance. DUBA exerts its effect by binding to the minor groove of DNA and causing alkylation, which leads to DNA damage and subsequent apoptosis, demonstrating potent antitumor efficacy.

Desmethyl Vc-seco-DUBA, a compound comprising a cleavable ADC linker (Desmethyl Vc-seco) and a DNA alkylating agent (DUBA), is utilized in the synthesis of antibody-drug conjugates (ADCs) [1].

Vobramitamab (AEX-4089) is a humanized monoclonal antibody (mAb) targeting the B7-H3 antigen (CD276) which is conjugated to the prodrug seco-duocarmycin hydroxybenzamide azaindole (seco-DUBA) through a enzymatically cleavable peptide-based linker, thereby creating the investigational antibody-drug conjugate (ADC) known as MGC018.